Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04721002 · ClinicalTrials.gov registry record
Study to Evaluate t(11;14) Status and BCL2 Expression in Adult Participants With Multiple Myeloma (MM)
A clinical trial, sponsored by AbbVie.
- Completed
- Registry status
- 514
- Enrollment target
NCT04721002 is a clinical trial that has completed, run by AbbVie. The registered enrollment target is 514 participants.
The verdict
NCT04721002 has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- 514 participants
- Enrollment target
Study Summary
Multiple myeloma (MM) is a rare cancer caused by abnormal survival of plasma cells (blood cells). Most trial participants with MM relapse (cancer has come back) or become non- responsive to treatment and remission gets shorter after each line of treatment. This is a study to assess t(11;14) and BCL2 expression in adult participants with newly diagnosed and relapsed/refractory (R/R) MM. Approximately 500 adult participants with newly confirmed or relapsed/refractory (R/R) multiple myeloma (MM) will be enrolled in around 15-20 countries. Participants will receive standard of care while participating in this study. No drug will be administered as a part of this study. Participants will attend regular visits during the course of the study at a hospital or clinic and will be asked to provide bone marrow and blood samples.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 514 participants |
| Start Date | 2021-07-07 |
| Est. Completion | 2023-09-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04721002
The ClinicalTrials.gov registry entry for NCT04721002 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 514 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT04721002 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04721002 about?
NCT04721002 is a clinical study titled "Study to Evaluate t(11;14) Status and BCL2 Expression in Adult Participants With Multiple Myeloma (MM)". Multiple myeloma (MM) is a rare cancer caused by abnormal survival of plasma cells (blood cells). Most trial participants with MM relapse (cancer has come back) or become non- responsive to treatment and remission gets shorter after each line of treatment. This is a study to assess t(11;14) and BCL2...
What is the current status of trial NCT04721002?
This trial is currently completed. The enrollment target is 514 participants. The study started on 2021-07-07. Estimated completion is 2023-09-30.
Who is sponsoring clinical trial NCT04721002?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.